August 2012
-
The non-profit Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) said that it has received an award of up to $3 million for development of a prototype antiviral nasal spray from the… Read more . . .
-
Codagenix said that it has completed a $25 million Series B extension financing, with funds primarily going to support development of its CodaVax-RSV intranasal live attenuated vaccine against respiratory syncytial virus. The FDA recently granted Fast Track… Read more . . .
-
Alveolus Bio has received a 3-year Small Business Innovation Research (SBIR) FastTrack grant worth approximately $2.5 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for development… Read more . . .
-
The FDA’s Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have voted unanimously in favor of over-the-counter use of Narcan naloxone nasal spray for the reversal of opioid overdose. In December 2022, the… Read more . . .
-
Inhaled drug developer Savara has announced the appointments of former Strongbridge Biopharma executives Scott Wilhoit as Executive VP, Global Commercial, and Rob Lutz as Chief Operating Officer. The company also said that it had promoted Dave Lowrance from… Read more . . .
-
ENA Respiratory announced that “an unexpectedly large proportion of participants having pre-existing immunity to the challenge strain” resulted in difficulties interpreting data from a Phase 2a flu challenge study of its INNA-051 pegylated TLR2/6 agonist nasal… Read more . . .
-
PureIMS has appointed Frank Lambert as Executive Director Commercialization. Lambert, who was most recently Executive Director of Business Development for Early Development Services at ICON, will lead commercialization efforts for the company’s Cyclops pre-filled disposable… Read more . . .
-
Researchers at North Carolina State University have published an article in Nature Materials describing preclinical development of an inhalation powder they are calling “SHIELD” (Spherical Hydrogel Inhalation for Enhanced Lung Defense) that has demonstrated the… Read more . . .
-
Copley Scientific has announced the launch of its next generation DUSA Shaker, a semi-automated tool for rinsing dose uniformity sampling apparatus (DUSA) collection tubes. According to the company, the the new DTS 100i is a… Read more . . .
-
Spexis has announced a deal with SPRIM Global Investments (SGI) for funding of up to half of Spexis’ costs related to Phase 3 development of ColiFin nebulized colistimethate sodium for the treatment of P. aeruginosa… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.